Value proposition

Freeox Biotech is an innovative late-stage clinical company singularly focused on the discovery and development of Cerebrovascular Protective Therapeutics. A Phase III-ready investigational drug – Ox-01, the company’s lead asset – has been shown to be an effective emergency adjunct therapy to Mechanical Thrombectomy for the treatment of Acute Ischemic Stroke (AIS).

Stroke, Oxidative stress, Neuroprotective therapies, Health research, Biotechnology, and Clinical research